Key Beast Risk: BMNR, 10%, OLMA

Stephanie Flanders leads a discussion on Donald Trump's influence on Washington and the global economy, featuring insights from Matt Levine and Katie Greifeld. They delve into Mr. Beast, the YouTube sensation known as Jimmy Donaldson, and his recent $200 million investment from Bitmine, which is aimed at acquiring a stake in Beast Industries. Mr. Beast is portrayed as a billionaire with a significant content creation empire, while Bitmine has evolved from a Bitcoin mining operation to a treasury company with approximately $14 billion in assets. The hosts explore the challenges faced by crypto treasury companies in the current market and Mr. Beast's growing influence in the crypto space, including speculation about his potential to promote Ethereum and the filing of a trademark for "Mr. Beast Financial," which intends to offer cryptocurrency exchange and consumer lending services.

The conversation shifts to consumer lending, highlighting high credit card interest rates and Donald Trump's proposal to cap them at 10%, a stance that contrasts with typical Republican views. The hosts analyze the implications of such caps on consumers and the economy, referencing research by Brian Shearer at Vanderbilt, which suggests that the credit card industry could lower rates while remaining profitable. They express skepticism about banks' claims that rate caps would harm their business model and discuss the potential shift of borrowers to payday lenders and the rise of buy now pay later options.

BILT is introduced as a company offering three new credit cards with a promotional interest rate of 10%, although this rate is temporary. The hosts emphasize BILT's unique market position, particularly its negotiations with landlords to allow rent payments via credit card, which is uncommon due to interchange fees. The discussion also touches on potential legal repercussions for Trump, with speculation about the consequences of his actions.

Mark Blyth discusses a recent insider trading case involving three brothers accused of manipulating healthcare stocks, highlighting the absurdity of the situation and the severe legal consequences faced by a banker involved. Concerns are raised about the implications of insider trading on drug trials, particularly regarding patient safety. The hosts explore the ethical complexities of insider trading in this context, concluding that personal experience with a product does not constitute insider trading.